MX2022014116A - Celulas madre pluripotentes inducidas (ipsc) modificadas. - Google Patents

Celulas madre pluripotentes inducidas (ipsc) modificadas.

Info

Publication number
MX2022014116A
MX2022014116A MX2022014116A MX2022014116A MX2022014116A MX 2022014116 A MX2022014116 A MX 2022014116A MX 2022014116 A MX2022014116 A MX 2022014116A MX 2022014116 A MX2022014116 A MX 2022014116A MX 2022014116 A MX2022014116 A MX 2022014116A
Authority
MX
Mexico
Prior art keywords
modified
cell
heterologous
modified ipscs
hemogenic
Prior art date
Application number
MX2022014116A
Other languages
English (en)
Spanish (es)
Inventor
Garth Hamilton
Christine Seidl
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Publication of MX2022014116A publication Critical patent/MX2022014116A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
MX2022014116A 2020-05-11 2021-05-11 Celulas madre pluripotentes inducidas (ipsc) modificadas. MX2022014116A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2006903.5A GB202006903D0 (en) 2020-05-11 2020-05-11 Modified iPSCs
PCT/GB2021/051125 WO2021229212A1 (en) 2020-05-11 2021-05-11 Modified ipscs

Publications (1)

Publication Number Publication Date
MX2022014116A true MX2022014116A (es) 2022-12-08

Family

ID=71135035

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014116A MX2022014116A (es) 2020-05-11 2021-05-11 Celulas madre pluripotentes inducidas (ipsc) modificadas.

Country Status (11)

Country Link
US (1) US20240016853A1 (https=)
EP (1) EP4149492A1 (https=)
JP (1) JP2023524853A (https=)
CN (1) CN115515606A (https=)
AU (1) AU2021271220A1 (https=)
BR (1) BR112022022654A2 (https=)
CA (1) CA3178047A1 (https=)
GB (1) GB202006903D0 (https=)
IL (1) IL298074A (https=)
MX (1) MX2022014116A (https=)
WO (1) WO2021229212A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2022714B1 (en) 2019-03-11 2020-09-18 Academisch Ziekenhuis Leiden Optimised RAG1 deficient SCID Gene Therapy
GB201911957D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of producing haemogenic progenitor cells from pluripotent stem cells
GB202111214D0 (en) * 2021-08-03 2021-09-15 Adaptimmune Ltd Modified ipscs
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
CN118421559B (zh) * 2024-07-04 2024-09-27 成都赛济元生物医药有限公司 定向分化淋巴造血前体细胞的小分子组合、试剂盒及方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
US12194083B2 (en) * 2014-07-18 2025-01-14 Hiroshi Kawamoto Method for establishing pluripotent stem cells bearing genes encoding antigen specific T cell receptor
JP6715482B2 (ja) * 2014-07-18 2020-07-01 国立大学法人京都大学 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法
SG11201803419PA (en) * 2015-10-30 2018-05-30 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
DK3440106T3 (da) * 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
EP4628587A3 (en) * 2016-04-15 2026-02-25 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
US20190290694A1 (en) * 2016-12-21 2019-09-26 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
US12350312B2 (en) * 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
SG11202101789SA (en) * 2018-07-26 2021-03-30 Univ Kyoto Method for generating cells into which an exogenous antigen receptor is introduced
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs

Also Published As

Publication number Publication date
WO2021229212A1 (en) 2021-11-18
CA3178047A1 (en) 2021-11-18
AU2021271220A1 (en) 2022-12-22
JP2023524853A (ja) 2023-06-13
CN115515606A (zh) 2022-12-23
BR112022022654A2 (pt) 2023-01-17
IL298074A (en) 2023-01-01
GB202006903D0 (en) 2020-06-24
US20240016853A1 (en) 2024-01-18
EP4149492A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
MX2022014116A (es) Celulas madre pluripotentes inducidas (ipsc) modificadas.
MX2020013977A (es) Proteínas quiméricas transmembrana y usos de las mismas.
CO2019006541A2 (es) Administración viral de neoantígenos
MX2026000627A (es) Transcripcion controlable
ECSP14028704A (es) Métodos y composiciones para la modificación de adn objetivo dirigida por arn y para la modulación de la transcripción dirigida por arn
CO2019013821A2 (es) Materiales y métodos para modificar células por ingeniería genética y usos de los mismos en inmunooncología
MX2023004505A (es) Polinucleotidos que contienen adn y guias para sistemas crispr de tipo v, y metodos de fabricacion y uso de los mismos.
BR112021014645A2 (pt) Método de edição de genes
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
CL2021001034A1 (es) Métodos y composiciones para terapia con células oculares
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
WO2019140116A3 (en) Amplifiable rnas for therapeutic cell systems
BR112019009746A2 (pt) ensaio de células-tronco pluripotentes
CL2017001903A1 (es) Composición novedosa para uso en el incremento de eficacia de injerto de células madre hematopoyéticas después del trasplante
MX2021001519A (es) Metodos para valorar acidos nucleicos integrados.
PE20131401A1 (es) Kit para detectar el virus de la leucemia bovina (blv), y uso del mismo
MX2021012207A (es) Composiciones y métodos para ensamblaje de genes del receptor de linfocitos t.
MX381412B (es) Métodos de cultivo semicontinuo.
CO2021011722A2 (es) Transactivadores de dominios de unión a adn y usos de estos
AR113812A1 (es) Estrategias para precisión en la edición del genoma
MX2020001058A (es) Marcadores de fusión para expresión de proteínas recombinantes.
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
BR112021019641A2 (pt) Kit, métodos e células de fluxo
MX2021012649A (es) Medio de cultivo celular para celulas eucarioticas.
MX2018000502A (es) Mejora del metabolismo de microalga de xilosa.